Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0002069239-26-000002
Filing Date
2026-01-02
Accepted
2026-01-02 21:00:09
Documents
1
Period of Report
2026-01-02

Document Format Files

Seq Description Document Type Size
1 form4-01022026_090103.html 4  
1 form4-01022026_090103.xml 4 5827
  Complete submission text file 0002069239-26-000002.txt   7280
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Issuer) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 10955 VISTA SORRENTO PARKWAY, SUITE 200 SAN DIEGO CA 92130
Business Address
Doyle Janeen Noel (Reporting) CIK: 0002069239 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40475 | Film No.: 26503696